Journal
JCI Insight
Publication Date
2-8-2024
Volume
9
Issue
3
First Page
e176359
Document Type
Open Access Publication
DOI
10.1172/jci.insight.176359
Rights and Permissions
Zimmerman O, Altman Doss AM, Ying B, Liang CY, Mackin SR, Davis-Adams HG, Adams LJ, VanBlargan LA, Chen RE, Scheaffer SM, Desai P, Raju S, Mantia TL, O'Shaughnessy CC, Monroy JM, Wedner HJ, Rigell CJ, Kau AL, Dy TB, Ren Z, Turner JS, O'Halloran JA, Presti RM, Kendall PL, Fremont DH, Ellebedy AH, Diamond MS. Immunoglobulin replacement products protect against SARS-CoV-2 infection in vivo despite poor neutralizing activity. JCI Insight. 2024 Feb 8;9(3):e176359. doi: 10.1172/jci.insight.176359. © 2024, Zimmerman et al. This is an open access article published under the terms of the Creative Commons Attribution 4.0 International License
Recommended Citation
Zimmerman, Ofer; Altman Doss, Alexa Michelle; Ying, Baoling; Liang, Chieh-Yu; Mackin, Samantha R.; Davis-Adams, Hannah G.; Adams, Lucas J.; VanBlargan, Laura A.; Chen, Rita E.; Scheaffer, Suzanne M.; Desai, Pritesh; Raju, Saravanan; Mantia, Tarisa L.; O'Shaughnessy, Caitlin C.; Monroy, Jennifer Marie; Wedner, H. James; Rigell, Christopher J.; Kau, Andrew L.; Dy, Tiffany Biason; Ren, Zhen; Turner, Jackson S.; O'Halloran, Jane A.; Presti, Rachel M.; Kendall, Peggy L.; Fremont, Daved H.; Ellebedy, Ali H.; and Diamond, Michael S, "Immunoglobulin replacement products protect against SARS-CoV-2 infection in vivo despite poor neutralizing activity." JCI Insight. 9, 3. e176359 (2024).
https://digitalcommons.wustl.edu/oa_4/3295
Department
ICTS (Institute of Clinical and Translational Sciences)
Additional Links
Supplemental material is available for this article at publisher site.
